Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12679269 | 0.86 | AKT1 (0.43) | SYKATMAPPCTSSCTSL | |
| SCHEMBL1529466 | 0.85 | DYRK1A (0.42) | DYRK1ADYRK1BAKT1 | |
| SCHEMBL12679257 | 0.83 | ATM (0.45) | SYKATMAPPCTSSDYRK1A | |
| SCHEMBL1529682 | 0.82 | DYRK1A (0.38) | DYRK1ADYRK1BCYP3A4ACKR3 | |
| SCHEMBL12679256 | 0.81 | ATM (0.45) | SYKATMAPPCTSSDYRK1A | |
| SCHEMBL12679237 | 0.78 | ATM (0.43) | SYKATMAPPCTSSCTSL | |
| SCHEMBL4543913 | 0.78 | HPGDS (0.36) | DYRK1ADYRK1BACKR3AKT1 | |
| SCHEMBL4583212 | 0.77 | ATM (0.52) | SYKATMAPPCTSSCTSL | |
| SCHEMBL12679233 | 0.77 | AKT1 (0.40) | SYKCTSSCTSKPCSK9ACKR3 | |
| SCHEMBL8240130 | 0.77 | AKT1 (0.43) | SYKATMAPPDYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8946278-B2 | Inhibitors of AkT activity | GLAXOSMITHKLINE LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946278-B2 | Inhibitors of AkT activity | GLAXOSMITHKLINE LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| CN-101646427-B | Inhibitors of akt activity | SMITHKLINE BEECHAM CORP US | 2013-06-12 | — | — | CN | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | disclosed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
| US-20160287561-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
| US-20110071182-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | SYK 599/4885ATM 2376/4885APP 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.